The ED90 of remimazolam for moderate sedation in children undergoing neurosurgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200067134

Enrollment

Unknown

Registered

2022-12-27

Start date

2023-01-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric neurosurgery

Interventions

experimental group: remimazolam

Eligibility

Sex/Gender

All

Age

No minimum to 6 Years

Inclusion criteria

Inclusion criteria: 1) The children who are scheduled to undergo elective neurosurgery under general anesthesia, 2) Age ranges from 3 months to 6 years.

Exclusion criteria

Exclusion criteria: 1) Allergy to benzodiazepine; 2) Use of benzodiazepine within recent one week; 3) Use of other sedatives such as propofol or midazolam within 24 hours before surgery; 4) Participation in other clinical studies within recent one month; 5) Refusal to participate.

Design outcomes

Primary

Measure	Time frame
ED90 of remimazolam for moderate sedation;	—

Secondary

Measure	Time frame
The intensity coefficient of the prefrontal-temporal brain network connection function;BIS value at moderate sedation;Pain scores within 3 days after surgery;Incidence of delirium within 3 days after surgery;	—

Countries

China

Contacts

Public ContactDongliang MU

Peking University First Hospital

mudongliang@icloud.com17810370608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026